Mihail Obrocea, M.D.Jeffrey C. Himmelreich, MBA
Dr. ObroceaMr. Himmelreich is our Chief Medical Officer. Dr. Obrocea isHead of Finance and principal financial and accounting officer, a hematologist/oncologist with over 20 years’ experience in drug development in both academia and the pharmaceutical/biotechnology industry with expertise in the development of cell therapy, cancer vaccines, monoclonal antibodies, and small molecules. Dr. Obrocea’s research has been published in oncology peer-reviewed literature,position he has co-authored published booksserved in since November 2023. From September 2023 to November 2023, Mr. Himmelreich acted as the Company’s Director of Accounting and Financial Reporting, where he provided oversight for the Company’s filings with the U.S. Securities and Exchange Commission and other related financial, accounting or reporting matters. From July 2021 to cancer vaccines and immunology, and he holds several patents inSeptember 2023, Mr. Himmelreich acted as the field of biotechnology. He received an M.D. degree from the Carol Davila University of Medicine & Pharmacy in Bucharest, Romania and completed an internship and residency program in Internal Medicine at Yale University affiliated hospitals in Connecticut followed by a hematology/oncology fellowship training program at Dartmouth Cancer Center and Geisel School of Medicine in Hanover, New Hampshire.
Joseph F. McGuire
Mr. McGuire is our Chief Financial Officer and he brings over 30 years of experienceMicrotech Knives, Inc., a private manufacturer of hand tools. Further, from December 2018 to MAIA havingJuly 2021, Mr. Himmelreich served as Chief Financial Officer for several privately heldthe Director of Finance and publicly traded companies in the health care, financial services, investment, and manufacturing industries. In these roles, his responsibilities included SEC financial reporting, investor relations, corporate governance, legal and audit liaison, and team building. Most recently, Mr. McGuire was the chief financial officerAccounting at Avadim Health Inc. (“Avadim”) from October 2014 to May 2021., a healthcare-related private company, during which time he assisted with SEC filings of Avadim subsequently filedHealth Inc. for a voluntary petition for protection under Chapter 11proposed initial public offering. Mr. Himmelreich has over 20 years of the U.S. Bankruptcy Codefinance, accounting and announced on August 17, 2021, the completion of its court-approved sale of substantially all of its assets to a newly createdpublic company and emergence from the reorganization proceedings under Chapter 11.reporting experience. Mr. McGuire began his career with Price Waterhouse, where he was a certified public accountant, and later held management positions with Dean Witter Reynolds and Paine Webber, Inc. Joe receivedHimmelreich has a Bachelor of Science (B.S.) in accountingAccounting from the Indiana University of Notre Dame.Pennsylvania, and a Master of Business Administration from Pennsylvania State University. Mr. Himmelreich holds an active CPA license from the state of Pennsylvania.
The collective experience of our leadership team includes involvement in the development, approval and/or commercialization of a number of major oncology drugs, including TARCEVA®TARCEVA®, NEXAVAR®NEXAVAR®, IMBRUVICA®XTANDI®, XTANDI®NERLYNX®, NERLYNX®TREANDA®, TREANDA®, TRISENOX®TRISENOX®, and ZOMETA®ZOMETA®, as well as numerous state-of-the-art development programs, including a telomerase inhibitor (IMETELSTAT®(IMETELSTAT®), a new immune oncology platform and agent (Cavrolotimod; AST-008), and novel nucleic acid based siRNA, andan antisense oligonucleotide therapeutics (NP/NPS-oligos). In addition, our team was involved in the development and approval of:
• | BREANZY®, an autologous CD19 chimeric antigen receptor (CAR T) treatment for B-cell lymphomas;
|
• | BESPONSA®, a CD22-directed antibody drug conjugate (ADC) for treatment of B-cell acute lymphoblastic leukemia; and
|
• | IMBRUVICA®IMBRUVICA®, or bruton tyrosine kinase inhibitor ibrutinib, for treatment of chronic lymphocytic leukemia and mantle cell lymphomas.
|
Non-Employee Directors
Louie Ngar Yee; Director
Ms. Louie has 30 years of service with HSBC Group in a variety of functions, principally with businesses of Global Banking and Markets including investment and securities management, asset management, and global research. She also held key leadership positions within Group Internal Audit of HSBC in Latin America, Asia Pacific, and United Kingdom.
Born and educated in Hong Kong, Ms. Louie joined HSBC as an executive trainee in Hong Kong and became an International Manager of HSBC Group in 1996. Since then, she has taken up different roles in Hong Kong, the Philippines, Indonesia, Taiwan, the United States, the United Kingdom, and Latin America, primarily in key management positions to lead, drive and execute a change agenda in a wide range of management situations including business re-engineering, business turnaround, business downsizing, and business set up.
Prior to her current appointment with MAIA Biotechnology in April 2020, Ms. Louie was the Group Chief Operating Officer of Group Internal Audit of HSBC Group.Group from January 2017 to March 2020.
We believe Ms. Louie is qualified to serve on our board of directors because she has extensive finance, compliance, and audit experience and expertise.